Corbus Pharmaceuticals Holdings, Inc. (CRBP)
4.05
-0.08
(-1.94%)
USD |
NASDAQ |
Oct 23, 16:00
4.04
-0.01
(-0.25%)
After-Hours: 20:00
Corbus Pharmaceuticals Holdings Net Income (Quarterly) : -35.04M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -35.04M |
| March 31, 2026 | -22.97M |
| December 31, 2025 | -20.56M |
| September 30, 2025 | -23.34M |
| June 30, 2025 | -17.66M |
| March 31, 2025 | -16.98M |
| December 31, 2024 | -9.53M |
| September 30, 2024 | -13.78M |
| June 30, 2024 | -9.997M |
| March 31, 2024 | -6.899M |
| December 31, 2023 | -8.021M |
| September 30, 2023 | -10.05M |
| June 30, 2023 | -8.784M |
| March 31, 2023 | -17.74M |
| December 31, 2022 | -10.88M |
| September 30, 2022 | -8.782M |
| June 30, 2022 | -13.25M |
| March 31, 2022 | -9.437M |
| December 31, 2021 | -10.26M |
| September 30, 2021 | -2.176M |
| June 30, 2021 | -17.14M |
| March 31, 2021 | -16.07M |
| December 31, 2020 | -8.612M |
| September 30, 2020 | -34.90M |
| June 30, 2020 | -38.11M |
| Date | Value |
|---|---|
| March 31, 2020 | -29.66M |
| December 31, 2019 | -26.58M |
| September 30, 2019 | -20.79M |
| June 30, 2019 | 2.153M |
| March 31, 2019 | -26.23M |
| December 31, 2018 | -17.31M |
| September 30, 2018 | -14.60M |
| June 30, 2018 | -12.07M |
| March 31, 2018 | -11.70M |
| December 31, 2017 | -10.69M |
| September 30, 2017 | -6.966M |
| June 30, 2017 | -7.297M |
| March 31, 2017 | -7.465M |
| December 31, 2016 | -7.570M |
| September 30, 2016 | -5.347M |
| June 30, 2016 | -4.189M |
| March 31, 2016 | -2.892M |
| December 31, 2015 | -2.499M |
| September 30, 2015 | -2.254M |
| June 30, 2015 | -2.562M |
| March 31, 2015 | -1.536M |
| December 31, 2014 | -1.260M |
| September 30, 2014 | -0.6596M |
| June 30, 2014 | -0.5046M |
| March 31, 2014 | -0.116M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 35.04M |
| EPS Diluted (Quarterly) | -1.805 |
| Enterprise Value | -38.06M |
| Earnings Yield | -152.5% |
| Normalized Earnings Yield | -152.51 |